2017
Pharmacogenetics in the Treatment of Pre-Eclampsia: Current Findings, Challenges and Perspectives
Abstract: Pre-eclampsia (PE) is defined as pregnancy-induced hypertension and proteinuria, and is a major cause of maternal and perinatal morbidity and mortality. A large subgroup of pregnant women with PE is nonresponsive to antihypertensive drugs, including methyldopa, nifedipine and hydralazine. Pharmacogenomics may help to guide the individualized therapy for this nonresponsive subgroup. However, just a few pharmacogenetic studies examined the effects of genetic polymorphisms on response to antihypertensive drugs in…
Search citation statements
Paper Sections
Select...
20
4
2
0
Citation Types
1
20
0
1
Year Published
Range
2018
2026
Publication Types
Select...
24
2
Relationship
0
26
Authors
Journals
Cited by 26 publications
(22 citation statements)
References 105 publications
1
20
0
1
Smart CitationsHow the paper below cites the one you are viewing
“…Indeed, lack of responsiveness to antihypertensive therapy in PE women is associated with worse outcomes, and there have been studies addressing this observation using pharmacodynamics tools to further understand which personalized approach could be beneficial for these patients. 17,18 A previous study analyzed the oxidative stress markers and nitric oxide availability in the plasma of PE women and found a higher total antioxidant capacity corroborating with what was found in this work, as well as lower carbonyl levels, a biomarker for protein oxidation. Lipid peroxidation measured using the thiobarbituric acid reactive substances (TBARS) method was not different between groups, but it was lower in the PE group when compared with the GH group, with nitrite levels significantly lower in both hypertensive groups.…”
Section: Discussion
supporting
confidence: 88%
Abstract